Clinically approved drugs, including vascular endothelial growth factor (VEGF) inhibitors and epidermal growth factor receptor (EGFR) inhibitors, are often accompanied by drug resistance and tumor recurrence.3, 4. This evidence concerns the gene VEGFA and neoplasm.